Start Date
June 30, 2004
Primary Completion Date
November 30, 2004
Study Completion Date
November 30, 2004
Lidoderm
Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
Celecoxib
Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
Hueytown
Mesa
Oro Valley
Phoenix
Carlsbad
Daytona Beach
Gainesville
Inverness
Melbourne
Miami
Port Orange
Sarasota
Decatur
Marietta
New Orleans
Bingham Farms
Clemmons
Winston-Salem
Duncansville
Johnstown
Lead Sponsor
Endo Pharmaceuticals
INDUSTRY